SCHEMBL25344167

SCHEMBL25344167

CCN(CCCn1cnc2cccc(Br)c21)C(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRPS1 P60891 1/20 0.42
NPSR1 Q6W5P4 2/20 0.38
SSTR4 P31391 1/20 0.38
MAPT P10636 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 1/20 0.36
NFKB1 P19838 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
HTT P42858 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NLRP3 Q96P20 1/20 0.34
NAMPT P43490 1/20 0.33
CPB2 Q96IY4 4/20 0.33
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30568608 1.00 PRPS1 (0.42) PRPS1NPSR1SSTR4MAPTSMN1; SMN2
SCHEMBL25343063 0.92 SSTR4 (0.45) PRPS1NPSR1SSTR4MAPTSMN1; SMN2
SCHEMBL30568651 0.92 SSTR4 (0.45) PRPS1NPSR1SSTR4MAPTSMN1; SMN2
SCHEMBL30568456 0.90 PRPS1 (0.39) PRPS1NPSR1SSTR4MAPTSMN1; SMN2
SCHEMBL25343570 0.90 PRPS1 (0.39) PRPS1NPSR1SSTR4MAPTSMN1; SMN2
SCHEMBL30568387 0.90 PRPS1 (0.39) PRPS1NPSR1SSTR4MAPTSMN1; SMN2
SCHEMBL25344234 0.87 PRPS1 (0.37) PRPS1NPSR1SSTR4MAPTSMN1; SMN2
SCHEMBL30568497 0.87 PRPS1 (0.37) PRPS1NPSR1SSTR4MAPTSMN1; SMN2
SCHEMBL25345315 0.84 PRPS1 (0.41) PRPS1NPSR1SSTR4MAPTSMN1; SMN2
SCHEMBL30568545 0.84 PRPS1 (0.41) PRPS1NPSR1SSTR4MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023148129-A1 IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2023-08-10 WO disclosed